167404-32-2Relevant academic research and scientific papers
CHEMICAL COMPOUNDS
-
Paragraph 0179-0181, (2021/04/02)
The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as Janus kinase (JAK) inhibitors and are useful in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.
Optimization of triaryl bis-sulfones as cannabinoid-2 receptor ligands
Lavey, Brian J.,Kozlowski, Joseph A.,Shankar, Bandarpalle B.,Spitler, James M.,Zhou, Guowei,Yang, De-Yi,Shu, Youheng,Wong, Michael K.C.,Wong, Shing-Chun,Shih, Neng-Yang,Wu, Jie,McCombie, Stuart W.,Rizvi, Razia,Wolin, Ronald L.,Lunn, Charles A.
, p. 3760 - 3764 (2008/02/12)
Structure-activity relationship on our recently reported triaryl bis-sulfone class of cannabinoid-2 (CB2) receptor selective inverse agonists was explored. Modifications to the methane sulfonamide, substitutions to B and C phenyl rings, and replacements o
CANNABINOID RECEPTOR LIGANDS
-
Page 38-39, (2008/06/13)
A compound of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein:R1, R2, L1, L2, M1, M2, n, p, q, A, D, X, Y and Z are as described in the specification; phar
Cannabinoid receptor ligands
-
Page 48, (2008/06/13)
The invention relates to compounds of the formula a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity. Also disclosed are pharmac
